Company
Chimeric Therapeutics Ltd
ASX:CHM
Chimeric Therapeutics Ltd, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. The company's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of today's most innovative solutions, and has shown a consistent ability to deliver on its objectives.
83 stories
Chimeric Therapeutics presents CHM 1101 Phase 1B clinical trial at ASCO annual scientific meeting
The ASCO abstract provided additional background data on one patient from the initial dose cohort that achieved survival of 15.5 months from time of 1st CHM 1101 infusion.
Chimeric Therapeutics in exclusive licence agreement with Case Western Reserve University for CORE-NK Platform
The CORE-NK platform uses a novel, proprietary genetically modified feeder cell line to activate and expand universal off-the-shelf allogeneic NK cell products derived from healthy donors.
Chimeric Therapeutics enters research agreement to further NK cell therapy portfolio
CWRU will work closely with Chimeric to advance multiple next-generation NK cell products through preclinical development.
Chimeric Therapeutics appoints clinical expert Dr Stephanie Astrow VP of translational sciences
“Dr [Stephanie] Astrow has extensive experience in the development of translational strategies for solid tumour and hematologic malignancies for adoptive cell therapies in both autologous and allogeneic settings," said CEO and MD Jennifer C
Chimeric Therapeutics granted Japanese patent covering applications of CLTX CAR technology
“We are delighted to have patent protection granted for CLTX CAR therapies in Japan, the third largest pharmaceutical market in the world,” CEO and MD Jennifer Chow said.
Chimeric Therapeutics appoints cell therapy industry leader as chief medical officer
Dr Jason B Litten brings almost 15 years of leadership in drug development with the past five years dedicated to advancing NK and CAR T cell therapy clinical-stage programs in oncology.
Chimeric Therapeutics strengthens management team with experienced clinical operations executive appointed vice president
“We are excited to welcome Cassandra as vice president Clinical Operations at Chimeric, a newly created but critically important position within our organisation,” said MD Jennifer Chow.
FIVE at FIVE AU: Energy stocks rise as ASX falls and Shell cops a please explain from unions over “choking” off gas supply
Here’s Proactive Australia’s round-up of the top local financial stories of the day, with helpful links taking you directly to the news.
Chimeric Therapeutics licenses viral vector technology from University of Pennsylvania for CDH17 CAR T program
The company has acquired a licence for the University of Pennsylvania's entiviral vector plasmid system, a viral vector technology critical for the manufacture of one of the company's main platforms - chimeric antigen receptor (CAR) T cells
Chimeric Therapeutics’ CORE NK platform features in clinical first trial combining IL-2 and Vactosertib
“With the initial positive results seen in the Phase 1A clinical trial with our CORE NK Platform cells, we have been eager to accelerate the development opportunities for it,” said Chimeric CEO Jennifer Chow.
Chimeric Therapeutics achieves key development milestone
“This marks a major milestone for advancing the development of CHM 1101,” says Chimeric CEO and managing director Jennifer Chow.
Chimeric Therapeutics signs A$30 million equity placement agreement with L1 Capital
The agreement comprises an initial share placement of A$5 million and up to an additional A$30 million in share placements over a 24-month period.
Chimeric Therapeutics takes first regulatory step towards IND for cancer drug CHM 2101
“We believe that CHM 2101 offers great promise for patients with gastrointestinal cancers and are very eager to move this asset to the clinic,” says MD.
Chimeric Therapeutics exercises exclusive option for CORE-NK platform
Chimeric expects to use the CORE-NK platform while leveraging its existing portfolio of CARs to pursue new clinical trials in blood cancers and solid tumours beginning in 2023.
Chimeric Therapeutics enters manufacturing partnership with Wuxi ATU to advance cancer pipeline
The new partnership will enable the company to accelerate clinical manufacturing readiness for new CAR T assets and to scale CAR T manufacturing to support multiple, simultaneous, multicenter CAR T clinical trials in the future.
Chimeric Therapeutics' CDH17 CAR-T preclinical trials published in Nature Cancer journal
In eight different in vivo models, including colorectal cancer, gastric cancer, pancreatic cancer and neuroendocrine tumours, the preclinical data demonstrate efficacy with minimal toxicity.
Chimeric Therapeutics concludes safety trial for blood and solid tumour cancer treatment; one patient in remission
The company’s CORE NK cell platform demonstrates "safety, substantial efficacy and robust expansion and persistence of universal donor NK cells".
Chimeric Therapeutics makes a match with Be The Match BioTherapies
“We have a shared commitment to advance next-generation cell therapies for waiting patients, and we intend to help them achieve their targets,” says Be The Match.
Chimeric Therapeutics’ rights issue will provide a longer runway to data readout: Diamond Equity Research
The company has opened the retail component of its rights offer, after raising about $7.37 million from the institutional component.
Chimeric Therapeutics opens retail component of ~$18 million rights issue
Proceeds from the rights issue will be used to continue advancement of Chimeric’s cell therapy development program which is expected to see the company with four Phase 1 clinical trials within the next 12 months.
Chimeric Therapeutics initiates third dose level of the CLTX CAR T Phase 1 trial for cancer patients
“With the encouraging safety and activity signs shown in the lower two dose levels we are excited to be advancing to the higher dose levels that may provide more therapeutic benefit to patients with progressive or recurrent glioblastoma,” s
Chimeric Therapeutics raises $7.37 million, with $10.75 million still to come from retail investors
The Retail Entitlement Offer is expected to raise approximately $10.75 million and will open on February 28 and close at 5pm on March 11.
Chimeric Therapeutics launches entitlement offer to raise $18 million
Chimeric is offering more than 106.5 million ordinary shares at $0.17 each to raise in excess of $18 million before costs. Funding will be used to support payments under the company’s licence and sponsored research agreements as well as Pha
Chimeric Therapeutics hitting milestones and pipeline flowing: RaaS Advisory
Chimeric is focused on developing and commercialising a range of chimeric antigen receptor T (CAR T) cell therapies targeting haematological cancers and solid tumours.
Chimeric Therapeutics observes “encouraging” data during glioblastoma dosing study in the US
The dose levels in the current study cohort were well tolerated, with disease stability also observed in some patients.
Chimeric Therapeutics to strengthen cell therapy quality systems with appointment of vice president
Kelly Thornburg has been advising the company as a consultant and will now serve in a leadership role to develop Chimeric’s quality systems and oversee all quality functions.
Chimeric Therapeutics inks sponsored research agreement for cancer studies with University of Pennsylvania
The company continues to make excellent progress towards a phase 1 clinical trial for CHM 2101 in neuroendocrine tumours and gastrointestinal adenocarcinomas.
Chimeric Therapeutics secures US patent for CLTX CAR technology key to advancing pipeline
“The granting of this key US patent continues the momentum for the intellectual property portfolio underpinning our CLTX CAR pipeline assets, following the recent patent grant in Europe in September," says CEO.
Chimeric Therapeutics has the opportunity to add a third partnership to its portfolio: RaaS Advisory
RaaS Advisory has valued Chimeric at a mid-case of A$243 million or A$0.74/share using a risked NPV based on its assumptions for CLTX CAR T therapy for recurrent glioblastoma (GBM), which is currently in Phase I trials.
Chimeric Therapeutics passes key milestone in cell therapy trials for cancer patients
The Chlorotoxin CAR T cell therapy is the first and best in class CAR T cell therapy which has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma.
Chimeric Therapeutics strengthens management team as it expands its portfolio
“Our recent portfolio growth has resulted in the need for expertise that will allow us to rapidly advance our preclinical assets alongside multiple phase 1 clinical trials in solid tumours and blood cancers,” said Chimeric’s CEO Jennifer Ch
Chimeric Therapeutics' valuation raised from $1.04 per share to $1.19 by Diamond Equity Research
The valuation hike is largely attributed to the acquisition of the option to license the CORE-NK cell platform targeting various solid tumours and blood cancers.
Chimeric Therapeutics initiated by Bioshares with 'Speculative Buy Class A' recommendation
The company is developing CAR T cell therapies for solid tumours based on scientific research conducted by the US CAR T experts at the City of Hope Cancer Centre in Los Angeles.
Chimeric Therapeutics set to lead cell therapy space following licensing deal on clinical platform
The licensing deal on CORE-NK, a platform developed by Case Western Reserve University in Ohio for next-generation clinical products targeting cancer, will enhance Chimeric's standing as a cell therapy leader.
Chimeric Therapeutics has coverage initiated by RaaS with mid-case valuation of $0.74 per share
RaaS expects to revisit the portfolio valuation as Chimeric progresses these assets beyond the pre-clinical stage.
Chimeric Therapeutics clinical data on glioblastoma treatment is "very promising"
The Phase 1 clinical trial suggests that CLTX CAR T may be effective even against the most aggressive cancers.
Chimeric Therapeutics’ CLTX CAR T Phase 1 trial confirms 75% disease control rate at lowest dose
“These initial CLTX CAR T clinical data, while early, are highly encouraging as they demonstrate that CLTX CAR T cells are eliciting disease control in recurrent glioblastoma even at the lowest, sub-therapeutic dose level," says CEO.
Chimeric Therapeutics has coverage initiated by Diamond Equity Research, attracts A$1.04 price target
Diamond Equity Research says: “We are initiating coverage of Chimeric Therapeutics with our valuation model indicating a fair value of A$1.04 per share, contingent on successful execution by the company.”
Chimeric Therapeutics achieves first milestone towards development of CDH17 CAR T
Phase 1 clinical trial for neuroendocrine and colorectal tumours are planned for 2022, positioning Chimeric to have a minimum of two phase 1 trials underway during 2022.
Chimeric Therapeutics has CHM 1101 data accepted for prestigious Society for Neuro-Oncology annual meeting
Chimeric Therapeutics developed CHM 1101 (CLTX CAR T) as a promising chimeric antigen receptor T cell therapy for the treatment of patients with Glioblastoma, the most common and aggressive malignant primary brain tumour in adults.
Chimeric Therapeutics granted European patent for cancer-fighting asset CHM 1101
CHM 1101 is Chimeric’s clinical-stage chlorotoxin CAR T therapy for solid tumours.
Chimeric Therapeutics appoints experts to Cellular Immunotherapy Scientific Advisory Board
The three appointments “bring deep translational expertise in cellular therapy development and are each very respected visionaries and contributors to the field,” says CEO & MD.
Chimeric Therapeutics forms partnership with OncoBay Clinical to advance CHM1101 development program
“With its experience managing the complexity of cell therapy research programs and scientific support from the Moffitt Cancer Center, we believe that the team at OncoBay is uniquely positioned to support the expansion of the CHM 1101 (CLTX
Chimeric Therapeutics ends FY21 well-funded with $22.4 million as it progresses CLTX CAR T
The company is the only ASX-listed biotech conducting clinical trials in CAR-T technology and is focused on Phase 1 clinical trials for its CLTX-CAR T therapy for solid tumours.
Chimeric Therapeutics appoints COO Jennifer Chow as new CEO and MD
“The team we’ve been able to assemble at Chimeric brings deep scientific and commercial cell therapy expertise to the business and gives us great confidence moving forward under Jenn’s leadership,” says chairman.
Chimeric Therapeutics receives IND clearance from US FDA for CHM 1101 for Glioblastoma
With this foundational IND, Chimeric will also further advance plans for a phase-I basket trial in solid tumours and a phase-II registration trial in Glioblastoma.
Chimeric Therapeutics director shows faith in cell therapy strategy with on-market purchase
The company’s new advisory board will be made up of world-class experts who have been directly involved in the development of multiple cellular immunotherapies.
Chimeric Therapeutics appoints Dr Yi Lin to cellular immunotherapy scientific advisory board
The board will be made up of world-class experts who have been directly involved in the successful development of multiple cellular immunotherapies.
Chimeric Therapeutics licenses novel CAR T cell therapy with “transformative potential” from the University of Pennsylvania
Thanks to an exclusive licensing agreement with “a powerhouse in CAR T innovation”, Chimeric believes it is a step closer to bringing cell therapy to life for cancer patients.
Chimeric Therapeutics ends June quarter in healthy financial position with $22.4 million as it progresses CLTX CAR T
The funds will support the company’s efforts to progress the development of CLTX CAR T and initiate the development of a cell therapy pipeline.
Chimeric Therapeutics appoints Celgene veteran Dr George Matcham to the board
Dr Matcham brings to Chimeric a wealth of experience in the biopharma sector, following an instrumental three decades with cell therapy giant Celgene Corporation.
Chimeric Therapeutics enhances cell therapy skillset with vice-president appointment
Dr Ren has nearly 20 years of experience developing and advancing cell therapy drug candidates from the preclinical stage through to commercial licensure.
Chimeric Therapeutics accelerates development of CAR T therapy as it looks to boost pipeline with additional therapies
The clinical-stage biotech company is looking at more curative therapies for patients with cancer, and not just therapies that delay disease progression.
Chimeric Therapeutics initiates second dose cohort in chlorotoxin CAR T cell phase 1 trial
The treatment of the first patient in the second dose cohort marks the introduction of dual routes of administration of CLTX CAR T cells with both ICT and ICV dosing.
Chimeric Therapeutics continues to develop oncology pipeline providing benefits to cancer patients globally
During the quarter, Chimeric completed a $35 million initial public offering (IPO) and successfully listed on the ASX with support from new and existing institutional, professional and retail investors within Australia and overseas.
Chimeric Therapeutics has CLTX CAR T abstract accepted for prestigious annual meeting of American Society of Clinical Oncology
CHM has exclusive global rights to IP covering the Chlorotoxin CAR T which is in development for patients with recurrent glioblastoma and is also being investigated for development in patients with other solid tumours such as melanoma, smal
Chimeric Therapeutics progresses to second dosing level with first patient cohort in CLTX CAR T Phase 1 trial
Chlorotoxin CAR T cell therapy is a first and potentially best in class therapy that has the potential to address the high unmet medical need of patients with recurrent/ progressive glioblastoma.
Chimeric Therapeutics has strong bank balance to progress ground-breaking CAR-T cell therapies for solid tumours
The biotech, which listed on the ASX on January 18, 2021, is developing its oncology pipeline with novel cell therapy technologies that will provide benefit to cancer patients globally.
Chimeric Therapeutics doses first patient cohort for Phase 1 CLTX CAR T trial
The objectives of the study are to evaluate the safety and efficacy of CLTX CAR T for patients with recurrent or progressive glioblastoma.
Chimeric Therapeutics non-executive director shows confidence in bio-tech strategy with on-market purchase
The purchase of 24,800 shares at A$0.3178 per share on March 8 was the first by Cindy Elkins.
Chimeric Therapeutics appoints business and corporate development VP to drive growth of cancer therapy pipeline
Dr Bourk will lead business and corporate development, with a near-term focus on Chimeric Therapeutics’ pipeline with additional novel cell therapies.
Chimeric Therapeutics appoints biotech industry veteran Cindy Elkins as a non-executive director
She has more than 30 years of experience in the biotech and high-tech industries, with roles at Juno Therapeutics, Genentech/Roche, and Ariba.
Chimeric Therapeutics appoints Dr Yvonne Chen from the University of California to scientific advisory board
The company is developing CAR T cell therapies for solid tumours based on scientific research conducted by leading American CAR T experts at the City of Hope (COH) Cancer Centre in Los Angeles.
Edison initiates coverage of Chimeric Therapeutics at 93 cents per basic share with launch of scorpion venom CAR-T seen in 2027 or earlier
If the data is strong enough, the approval timeline may be accelerated due to the high unmet medical need in GBM.
Chimeric Therapeutics lists on ASX after being swamped by IPO investor support
The company is the only ASX-listed biotech conducting clinical trials in CAR-T technology and is focused on Phase 1 clinical trials for its CLTX-CAR T therapy for solid tumours.